Encouraging five year clinical data for novel next generation Immuno-Oncology therapy In lung cancer presented at ESMO 2017 Congress

Oct 12, 2017

Copenhagen, Denmark – October 12, 2017: IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today announced encouraging five year clinical data for novel next generation Immuno-Oncology therapy in lung cancer presented at ESMO 2017 Congress

Other news

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Provides Business Update

IO Biotech Provides Business Update